Sandoz’ Saynor Insists US Biosimilars Market Is Stepping Up
US And Europe Were Once ‘Venus And Mars’ – But Promising Signs Emerging
Sandoz CEO Richard Saynor says he sees promising signs from the US biosimilars market that suggest it is beginning to meet its potential, albeit remaining many years behind the European market.
You may also be interested in...
With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.
Five years on from the first US biosimilar approval, the country’s biosimilars market is starting to fulfil its potential, in part driven by a recent oncology “revolution” according to Sandoz’ Sheila Frame.
Dispelling myths around biosimilar efficacy and safety may be crucial to driving uptake of biosimilars, executives from Sandoz and Boehringer Ingelheim have argued in an opinion piece in the journal, BioDrugs, as they asserted it was the “responsibility of all stakeholders to challenge biosimilar disparagement and misinformation when encountered.”